Dr. Martens Plc stock analysis
Want to see GB:DOCS full AI Analyst Report?
Dr. Martens Plc (DOCS) Share Price & Analysis
DOCS Stock Chart & Stats
- Day’s Range
- GBX 54.50 - GBX 57.00
- 52-Week Range
- GBX 50.80 - GBX 90.00
- Previous Close
- GBX 56.10
- Volume
- N/A
- Average Volume (3M)
- 2.25M
- Market Cap
- GBP 533.24M
- Enterprise Value
- GBP 952.18M
- Total Cash (Recent Filing)
- GBP 91.10M
- Total Debt (Recent Filing)
- GBP 400.90M
- Price to Earnings (P/E)
- 19.3
- Beta
- 1.39
- Next Earnings
- Jun 03, 2027 (Est.)
- EPS Estimate
- 0.05
- Next Dividend Ex-Date
- Mar 04, 2027
- Dividend Yield
- 4.55%
Bulls Say, Bears Say
Bulls Say
Cash Generation And Conversion
Solid free cash flow and close alignment with operating cash flow indicate effective earnings conversion and support ongoing investment, debt service, and shareholder distributions. This provides financial resilience while management works to restore revenue growth, although yearly cash generation remains somewhat volatile.
Margin Resilience And Cost Control
Cost actions, a simplified operating model, and disciplined pricing helped offset lower volumes and preserve profitability. Sustained control of operating expenses and gross margin can protect cash generation and create operating leverage if product demand improves over the next several quarters.
Brand And Product Development
Growth in shoes and sandals, alongside broad global brand activation, shows that demand is not limited to the core boot franchise. Expanding product categories and reinforcing brand engagement could diversify revenue and support longer-term growth as the company rebuilds its footwear portfolio.
Bears Say
Multi-year Revenue And Profit Deterioration
Persistent revenue contraction and materially lower profitability indicate that the business has not yet restored its prior earnings power. Even with a 2026 operating-margin rebound, weaker scale and compressed net returns reduce reinvestment capacity and leave performance dependent on successful recovery.
Core Boots Weakness
The core boot franchise remains the principal drag on sales, with management acknowledging that recovery will take time. Because boots are central to the brand proposition, prolonged weakness can limit overall growth, dilute operating leverage, and force newer categories to compensate before the core business stabilizes.
DTC Disruption And Execution Risk
Direct-to-consumer performance and the platform transition require continued disciplined execution, affecting an important route to market and customer experience. Ongoing disruption could delay sales recovery, weaken channel productivity, and make the company more reliant on wholesale while digital operations mature.
Dr. Martens Plc News
DOCS FAQ
What was Dr. Martens Plc’s price range in the past 12 months?
What is Dr. Martens Plc’s market cap?
When is Dr. Martens Plc’s upcoming earnings report date?
How were Dr. Martens Plc’s earnings last quarter?
Is Dr. Martens Plc overvalued?
Does Dr. Martens Plc pay dividends?
What is Dr. Martens Plc’s EPS estimate?
How many shares outstanding does Dr. Martens Plc have?
What happened to Dr. Martens Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dr. Martens Plc?
What is the TipRanks Smart Score and how is it calculated?
Dr. Martens Plc Stock Smart Score
Company Description
Dr. Martens Plc
Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.
- Sector
- Consumercyclical
- Industry
- Apparel - Footwear & Accessories
- CEO
- Ije Nwokorie
- Employees
- 2,377
- Website
- www.drmartensplc.com
- Address
- 28 Jamestown Road, London, GL, NW1 7BY, GB
Dr. Martens Plc (DOCS) Earnings & Revenues
DOCS Earnings Call
Earnings Call SentimentNeutral
The call presented a mixed outlook. First-half revenue and profitability were weak, with a 9.2% constant-currency revenue decline, losses at the adjusted EBIT and adjusted PBT levels, significant boots pressure, and negative cash generation. However, management highlighted resilient gross margin, cost savings, strong wholesale and selected market performance, progress in shoes and sandals, major brand and platform launches, a healthy balance sheet, and unchanged medium-term objectives. The call was transparent about substantial execution work still required, resulting in a balanced overall tone.
View all GB:DOCS earnings summariesDOCS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |









